US Stock MarketDetailed Quotes
DAWN Day One Biopharmaceuticals
- 13.720
- +0.180+1.33%
Close Nov 27 16:00 ET
- 13.720
- 0.0000.00%
Post 20:01 ET
1.38BMarket Cap-14144P/E (TTM)
13.780High13.500Low584.19KVolume13.600Open13.540Pre Close7.98MTurnover0.84%Turnover RatioLossP/E (Static)100.85MShares18.07052wk High2.49P/B951.98MFloat Cap11.51052wk Low--Dividend TTM69.39MShs Float28.699Historical High--Div YieldTTM2.07%Amplitude5.440Historical Low13.667Avg Price1Lot Size
Day One Biopharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 236.93%50.75M | -15.78%-49.13M | -91.38%-49.73M | -33.66%-146.85M | -17.17%-41.37M | -59.66%-37.06M | -42.45%-42.43M | -20.51%-25.99M | -126.36%-109.87M | -168.13%-35.31M |
| Net income from continuing operations | 180.25%37.04M | 90.39%-4.41M | -47.22%-62.41M | -32.87%-188.92M | -35.91%-54.51M | -22.11%-46.15M | -25.55%-45.86M | -52.78%-42.39M | -95.43%-142.18M | -82.83%-40.11M |
| Operating gains losses | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 653.54%746K | 343.48%408K | 30.34%116K | -27.87%383K | -42.78%103K | -40.00%99K | -30.83%92K | 67.92%89K | 166.83%531K | 252.94%180K |
| Other non cash items | ---- | ---- | ---- | --3M | --0 | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | -5,254.56%-52.21M | 5,872.13%50.74M | -83.74%1.22M | 43.48%9.42M | 412.84%3.8M | -114.19%-975K | -189.79%-879K | 10,622.54%7.47M | 143.56%6.56M | -133.38%-1.22M |
| -Change in receivables | --441K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Change in inventory | ---2.55M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Change in prepaid assets | 191.15%752K | -56.80%-3.87M | -35.85%884K | -262.53%-3.07M | -311.15%-1.16M | -154.93%-825K | 25.78%-2.47M | 223.47%1.38M | 77.61%-846K | -48.40%547K |
| -Change in payables and accrued expense | -120,139.13%-55.31M | 3,696.85%63.98M | -92.91%439K | 66.17%12.89M | 416.57%5.06M | -100.85%-46K | -61.42%1.69M | 1,481.47%6.19M | 16.54%7.76M | -161.31%-1.6M |
| -Change in other current liabilities | 43.27%-59K | -11.11%-110K | -12.50%-108K | -16.71%-405K | 34.97%-106K | -52.94%-104K | -47.76%-99K | -95.92%-96K | -90.66%-347K | -482.14%-163K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 236.93%50.75M | -15.78%-49.13M | -91.38%-49.73M | -33.66%-146.85M | -17.17%-41.37M | -59.66%-37.06M | -42.45%-42.43M | -20.51%-25.99M | -126.36%-109.87M | -168.13%-35.31M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -176.14%-67.7M | -15.87%17.06M | 897.71%89.29M | 150.33%128.38M | 1,474.66%30.38M | 136.02%88.92M | 438.07%20.27M | -74,520.00%-11.19M | -3,088.43%-255.07M | -2.21M |
| Net PPE purchase and sale | -1,665.85%-724K | 82.55%-26K | --0 | -761.54%-224K | ---8K | -925.00%-41K | -2,028.57%-149K | -73.33%-26K | ---26K | --0 |
| Net intangibles purchase and sale | -1,733.33%-55M | ---- | ---- | ---3M | --0 | ---3M | ---- | ---- | --0 | --0 |
| Net investment purchase and sale | -113.02%-11.98M | -461.44%-73.82M | 899.57%89.29M | 151.60%131.6M | 1,475.02%30.39M | 137.25%91.96M | 440.95%20.42M | ---11.17M | ---255.05M | ---2.21M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -176.14%-67.7M | -15.87%17.06M | 897.71%89.29M | 150.33%128.38M | 1,474.66%30.38M | 136.02%88.92M | 438.07%20.27M | -74,520.00%-11.19M | -3,088.43%-255.07M | ---2.21M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 173,895.65%200.1M | -99.20%1.3M | -95.95%48K | -1.15%164M | -68.87%597K | -94.40%115K | 0.11%162.1M | 1.18M | -44.16%165.9M | 503.14%1.92M |
| Net common stock issuance | --178.18M | ---- | ---- | -0.12%161.41M | --0 | --0 | ---- | ---- | -3.25%161.61M | --0 |
| Net preferred stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| Proceeds from stock option exercised by employees | 18,959.13%21.92M | 87.43%1.3M | -95.95%48K | -39.69%2.59M | -68.87%597K | -94.40%115K | 116.25%692K | --1.18M | 1,249.37%4.29M | 503.14%1.92M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 173,895.65%200.1M | -99.20%1.3M | -95.95%48K | -1.15%164M | -68.87%597K | -94.40%115K | 0.11%162.1M | --1.18M | -44.16%165.9M | 503.14%1.92M |
| Net cash flow | ||||||||||
| Beginning cash position | 26.64%239.62M | 448.82%270.39M | 170.68%230.78M | -70.01%85.26M | 99.55%241.18M | -51.34%189.21M | -81.25%49.27M | -70.01%85.26M | 550.18%284.31M | -59.33%120.86M |
| Current changes in cash | 252.43%183.15M | -121.99%-30.78M | 210.04%39.61M | 173.11%145.52M | 70.80%-10.4M | 119.39%51.97M | 10.94%139.94M | -66.81%-35.99M | -182.74%-199.05M | -177.04%-35.6M |
| End cash Position | 75.29%422.77M | 26.64%239.62M | 448.82%270.39M | 170.68%230.78M | 170.68%230.78M | 99.55%241.18M | -51.34%189.21M | -81.25%49.27M | -70.01%85.26M | -70.01%85.26M |
| Free cash flow | 87.61%-4.97M | -55.60%-66.26M | -91.18%-49.73M | -36.56%-150.08M | -17.19%-41.38M | -72.73%-40.11M | -42.92%-42.58M | -20.54%-26.01M | -94.38%-109.9M | -168.13%-35.31M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data